证券代码：300452 证券简称：山河药辅 公告编号：2025-056 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等法律、行政法规、部门 规章、规范性文件及《公司章程》的有关规定。 1、本次股东会提案编码表 4、会议时间： （1）现场会议时间：2025 年 11 月 06 日 15:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 06 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 11 月 06 日 9:15 至 15:00 的任意时间。 5、会 ...

证券代码：300452 证券简称：山河药辅 公告编号：2025-054 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 安徽山河药用辅料股份有限公司（以下简称"公司"）第六届董事会 第八次会议于 2025 年 10 月 20 日上午在公司三楼会议室召开，应出席会 议董事 7 人，实际出席会议董事 7 人。公司第六届董事会第八次会议通知 已于 2025 年 10 月 17 日以电子邮件、传真及电话通知的方式向全体董事 送达，会议由代理董事长宋道才先生主持。会议的召开符合《中华人民共 和国公司法》和《公司章程》的有关规定。本次会议经审议逐项表决作出 如下决议： 一、审议通过《关于公司 2025 年第三季度报告的议案》 第六届董事会第八次会议决议公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏。 公司拟定于 2025 年 11 月 6 日（星期四）下午3 点，在公司三楼会 议室召开 2025 年第二次临时股东会，会期半天。 具体内容详见同日披露在巨潮资讯网（http://www.cninfo.com.cn） 的《关于召开 2025 年第二次临时股东会的 ...

安徽山河药用辅料股份有限公司 2025 年第三季度报告 证券代码：300452 证券简称：山河药辅 公告编号：2025-053 安徽山河药用辅料股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 225,663,160.30 | 16.06% | 696,502,709.90 | 8.09 ...

证券代码：300452 证券简称：山河药辅 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 向不特定对象发行可转换公司债券 第二次临时受托管理事务报告 （2025 年度） 债券受托管理人 （安徽省合肥市梅山路 18 号） 二〇二五年十月 重要声明 本报告依据《公司债券发行与交易管理办法》（以下简称《管理办法》）、 《公 司债券受托管理人执业行为准则》（以下简称 《行为准则》）、 《安徽山河药用辅料 股份有限公司向不特定对象发行可转换公司债券之受托管理协议》（以下简称《受 托管理协议》）、《安徽山河药用辅料股份有限公司向不特定对象发行可转换公司 债券并在创业板上市募集说明书》（以下简称《募集说明书》）等相关规定、公开 信息披露文件、安徽山河药用辅料股份有限公司 （以下简称山山河药辅、、山发行 人、或山公司、）提供的相关资料等，由本期债券受托管理人国元证券股份有限 公司（以下简称山国元证券、）编制。国元证券对本报告中所包含的从上述文件 中引述内容和信息未进行独立验证，也不就该等引述内容和信息的真实性、准确 性和完整性做出任何保证或承担任何责任。 本报告不构成对投资者进行或不进行某项行为的 ...

证券代码：300452 证券简称：山河药辅 公告编号：2025-052 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 关于 2025 年第三季度可转债转股情况的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 特别提示： 1、"山河转债"（债券代码：123199）的转股期限为 2023 年 12 月 18 日起至 2029 年 6 月 11 日；最新的转股价格为人民币 13.30 元/股； 2、2025 年第三季度，共有 50 张"山河转债"（票面金额共计 5,000 元人民币）完成转股，合计转成 375 股"山河药辅"股票； 3、截至 2025 年第三季度末，共有 1,787 张"山河转债"（票面 金额共计 178,700 元人民币）完成转股，合计转成 12,191 股"山河 药辅"股票；公司剩余可转债数量为 3,198,213 张，剩余票面总金 额为 319,821,300 元人民币。 根据《深圳证券交易所股票上市规则》、《深圳证券交易所上市 公司自律监管指引第 15 号——可转换公司债券》的有关规定，安徽 山河药用辅料股份有限公司（以下 ...

北京市东城区朝阳门内大街南竹杆胡同 2 号银河 SOHO5 号楼 邮编：100010 电话：（8610）6642 8877 传真：（8610）6642 6100 Building 5, Galaxy SOHO, No.2 Nanzhuganhutong,ChaoyangmenneiAvenue, Dongcheng District,Beijing, 100010 中诚信国际认为，本次公司控股股东、实际控制人变更事项系夫妻共同财产 分割及遗产继承事项产生，目前公司经营及治理结构保持稳定，上述事项暂未对 公司整体信用水平产生重大不利影响，中诚信国际将持续关注上述股权变更事 项对公司未来经营管理和发展战略的影响。 特此公告 中诚信国际信用评级有限责任公司 中诚信国际关于关注安徽山河药用辅料股份有限公司 控股股东、实际控制人发生变更的公告 安徽山河药用辅料股份有限公司（以下简称"山河药辅"或"公司"）发行 的"山河转债"由中诚信国际信用评级有限责任公司（以下简称"中诚信国际"） 进行相关评级工作。 近日，公司发布《安徽山河药用辅料股份有限公司关于控股股东、实际控制 人发生变更暨股东权益变动的提示性公告》和《安徽山河 ...

Group 1 - Pingzhi Information has been selected as the eighth candidate for the "2025 China Unicom General Server Centralized Procurement Project" with a bid amount of approximately 451 million yuan [1] - The project involves the procurement of general servers primarily for cloud computing infrastructure [1] - Pingzhi Information was established in November 2002 and focuses on communication equipment, computing power, and operator equity products [1] Group 2 - Betta Pharmaceuticals has submitted an application for the issuance of H shares and listing on the Hong Kong Stock Exchange [2] - Betta Pharmaceuticals was founded in January 2003 and specializes in the production and sales of innovative drugs [2] Group 3 - Guangli Micro plans to sign an agreement with Zhejiang University to establish a joint research center for silicon photonics technology and measurement equipment [3] - The company will invest no less than 15 million yuan over three years for the center's development [3] - Guangli Micro was founded in August 2003 and provides a range of services including integrated circuit manufacturing and design [3] Group 4 - Shanhe Pharmaceutical's controlling shareholder and actual controller has changed due to the passing of Yin Zhenglong, with his wife and daughter inheriting shares [4] - After the change, Wu Changhong holds 20.172% of the total shares, while Yin Zhiya holds 6.724% [4] - Shanhe Pharmaceutical was established in April 2001 and focuses on the research, production, and sales of pharmaceutical excipients [5] Group 5 - Hengwei Technology plans to acquire 75% of Shanghai Shuhang Information Technology Co., Ltd. through a combination of share issuance and cash payment [6] - The acquisition will make Shuhang Technology a subsidiary of Hengwei Technology [6] - Hengwei Technology was founded in March 2003 and specializes in intelligent system solutions [7] Group 6 - Shougang Co. intends to repurchase its A-shares for an amount between 260 million yuan and 520 million yuan [8] - The repurchase will be used for implementing an equity incentive plan [8] - Shougang Co. was established in October 1999 and focuses on the production and sales of steel products [9] Group 7 - Pulit plans to build a 6GWh sodium-ion battery production base in Sichuan with a total investment of approximately 800 million yuan [10] - The project will be constructed in two phases, with the first phase having a capacity of 2GWh [10] - Pulit was founded in October 1999 and specializes in high polymer new materials and battery production [10] Group 8 - Saisir has proposed a cash dividend of 3.1 yuan per 10 shares for its A-share shareholders [10] - Saisir was established in May 2007 and focuses on the research, manufacturing, and sales of new energy vehicles [10] Group 9 - Guangyang Co. plans to establish a wholly-owned subsidiary for the development of precision components for robots [11] - The investment is part of a project to produce high-end components for new energy vehicles and robots [11] - Guangyang Co. was founded in April 1995 and specializes in precision components for various vehicles and equipment [11] Group 10 - Conch New Materials intends to acquire a 51% stake in North China Industrial Plastics Co., Ltd. for approximately 95.27 million yuan [12] - The acquisition will make North China Plastics a subsidiary of Conch New Materials [12] - Conch New Materials was established in October 1996 and focuses on the production and sales of plastic profiles and aluminum profiles [12] Group 11 - Daikin Heavy Industries has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [13] - The company specializes in the production and sales of offshore wind power equipment [13] - Daikin Heavy Industries was founded in September 2003 [13] Group 12 - Tengya Precision plans to invest up to 8 million USD to establish a subsidiary in Vietnam for the production of garden robots and electric tools [14] - The project will involve leasing a factory in Dong Nai Province [14] - Tengya Precision was established in August 2000 and focuses on power tools and building hardware [15] Group 13 - Luoxin Pharmaceutical plans to raise up to 207 million yuan through a private placement for innovative drug research and development [16] - The funds will primarily support clinical research for specific innovative drugs [16] - Luoxin Pharmaceutical was founded in May 1998 and specializes in pharmaceutical product development [17] Group 14 - *ST Guohua's subsidiary has become the first candidate for a project with a bid of 236 million yuan [18] - The project involves a 90-day construction period [18] - *ST Guohua was established in May 1986 and focuses on mobile network security [19] Group 15 - Su Chen Technology plans to acquire 60% of Likong Technology for a total price of 192 million yuan [20] - The acquisition will make Likong Technology a secondary subsidiary of Su Chen Technology [20] - Su Chen Technology was founded in February 2006 and specializes in CAE software development [21] Group 16 - Qingmu Technology's major shareholder plans to reduce their stake by up to 276,000 shares [22] - The reduction is due to the shareholder's financial needs [22] - Qingmu Technology was established in August 2009 and provides comprehensive e-commerce operation services [23] Group 17 - Tongda Sea plans to acquire 40% of Jiangsu Sufuda Data Technology Co., Ltd. for 25.64 million yuan [24] - The acquisition will result in Tongda Sea holding 100% of Sufuda [24] - Tongda Sea was founded in March 1995 and provides information technology services for electronic government affairs [24] Group 18 - Rongsheng Development has signed a memorandum of cooperation to promote the development of the seaplane industry [25] - The cooperation will focus on infrastructure construction and talent training [25] - Rongsheng Development was established in December 1996 and specializes in real estate development [26] Group 19 - Jinma Amusement plans to repurchase 16.52% of its subsidiary for 60 million yuan [28] - The repurchase will convert the subsidiary into a wholly-owned entity [28] - Jinma Amusement was founded in November 2007 and focuses on amusement facilities and projects [28] Group 20 - Huilv Ecology plans to acquire 49% of Junheng Technology for 1.127 billion yuan [29] - The acquisition will make Junheng Technology a wholly-owned subsidiary [29] - Huilv Ecology was established in January 1990 and specializes in optical communication products and landscape engineering [30]

Group 1: Major Asset Restructuring - Guolin Technology is planning a significant asset restructuring by acquiring 91.07% of Xinjiang Kailianjie Petrochemical Co., Ltd. for cash, which will give the company control over Kailianjie, making it a subsidiary [1][2] Group 2: Equity Purchases and Stock Suspension - Diaowei is planning to purchase equity in Rongpai Semiconductor through a combination of issuing shares and cash payments, leading to a stock suspension from September 29, 2025, for up to 10 trading days [3] - Bicheng Co. is also planning to acquire 55% of Shanghai Canxi Engineering Equipment Co., Ltd. through issuing shares and cash, with a stock suspension starting September 30, 2025, for up to 5 trading days [7] Group 3: Changes in Control - Shanhe Pharmaceutical Auxiliary announced a change in its controlling shareholder and actual controller to Wu Changhong due to the inheritance following the death of the previous controller, Yin Zhenglong [4] Group 4: Earnings Forecasts - Yinglian Co. expects a net profit of 34.5 million to 37.5 million yuan for the first three quarters of 2025, representing a year-on-year increase of 1531.13% to 1672.97%, driven by the fast-moving consumer goods metal packaging sector [5] - Dalian Heavy Industry anticipates a net profit of 474 million to 508 million yuan for the same period, reflecting a growth of 19.91% to 28.52% year-on-year, attributed to steady revenue growth [5] Group 5: Fundraising and Projects - Zhongcai Technology plans to raise up to 4.481 billion yuan through a private placement to fund projects related to low dielectric fiber cloth production and to repay government funds [8] - Luoxin Pharmaceutical is also looking to raise up to 842.4 million yuan for innovative drug research and development and facility upgrades [8] Group 6: Regulatory Actions - *ST Xingnong has been investigated by the China Securities Regulatory Commission for suspected information disclosure violations [9] - Other companies, including Youkeshi and Woton Technology, are also involved in various regulatory and investment activities, including share buybacks and strategic partnerships [10][14]

格隆汇9月29日丨山河药辅(300452.SZ)公布，在本次权益变动前，吴长虹女士、尹稚雅女士未直接或间 接持有公司股份。2025年8月26日，公司原控股股东、实际控制人尹正龙先生逝世。尹正龙先生直接持 有公司63,057,454股股份，占公司总股本的26.896%，为公司原控股股东、实际控制人。 根据淮南市正诚公证处出具的《公证书》（2025）皖淮正公证字第7078号），尹正龙先生生前无遗嘱， 亦未与他人签订遗赠扶养协议。根据《民法典》相关规定，被继承人尹正龙先生遗产应由其妻子吴长 虹、女儿尹稚雅两人共同继承。本次权益变动后吴长虹女士将直接持有山河药辅47,293,091股股票，占 山河药辅总股本的20.172%，尹稚雅女士将直接持有山河药辅15,764,363股股票，占山河药辅总股本的 6.724%。同时，吴长虹女士与尹稚雅女士签署了《表决权委托协议》，尹稚雅女士将其所持有山河药 辅全部股份的身份性权利，包括（但不限于）参会权、提名权、提案权、表决权等身份性权利全部委托 吴长虹女士行使。至此，吴长虹女士持有63,057,454股山河药辅表决权，占公司有表决权股份总数的比 例为26.896%。山河药辅控股股 ...

根据淮南市正诚公证处出具的《公证书》（2025）皖淮正公证字第7078号），尹正龙先生生前无遗嘱， 亦未与他人签订遗赠扶养协议。根据《民法典》相关规定，被继承人尹正龙先生遗产应由其妻子吴长 虹、女儿尹稚雅两人共同继承。本次权益变动后吴长虹女士将直接持有山河药辅47,293,091股股票，占 山河药辅总股本的20.172%，尹稚雅女士将直接持有山河药辅15,764,363股股票，占山河药辅总股本的 6.724%。同时，吴长虹女士与尹稚雅女士签署了《表决权委托协议》，尹稚雅女士将其所持有山河药 辅全部股份的身份性权利，包括（但不限于）参会权、提名权、提案权、表决权等身份性权利全部委托 吴长虹女士行使。至此，吴长虹女士持有63,057,454股山河药辅表决权，占公司有表决权股份总数的比 例为26.896%。山河药辅控股股东、实际控制人由尹正龙先生变更为吴长虹女士。 本次权益变动完成后，公司控股股东、实际控制人由尹正龙先生变更为吴长虹女士，尹稚雅女士为其一 致行动人。公司本次控股股东、实际控制人变更系因夫妻共同财产分割及遗产继承事项发生变动，不会 影响公司经营的稳定性，不会引起公司管理层变动，亦不会影响公司的独立性和 ...